On February 28, rare-disease communities around the world come together to advocate for an increase in research focused on rare diseases. When it comes to clinical research for rare and orphan diseases, the relationship with the patient and advocacy groups is critical to success.
patient and physician services
Competing studies can be a challenge when enrolling patients in clinical trials. But when those studies are conducted by one sponsor, the need to engage with a single patient population can quickly turn into an asset and huge savings.
When the August heat has you running for the pool, and it seems like the whole world is on vacation, it can be hard to think ahead to fall. However, when it comes to patient recruitment for clinical research, this is a very important time.
I moved to Boston recently, and I’m still figuring out the lay of the land. Even when I’m sure of my destination, my app usually re-routes me and I sometimes find a shorter way to get there.
The same can be said for clinical trial recruitment strategies. In the summer months, we find that a lot of our clients are re-assessing. How is the study tracking to its milestones? What goals have been communicated to senior management?
Even the most reluctant among us are coming around to social media, with 2.31 billion users now active on social media globally. Still pharmaceutical and biotech companies have been slow to embrace social media for clinical trials. Why?
In my previous post, I discussed ways to navigate some of the roadblocks that may impede your ability to enrol patients during the summer months. With those strategies firmly in place, it’s important to take advantage of a slow-down in activities to plan for the future.
The summer season is fast approaching and that can only mean one thing – summer holidays. There is one sure thing to cause frustration and delays in reaching your vacation destination – roadblocks. Whilst on holiday, I tend to do all of the driving and I know that in order to reduce the chances of getting caught up in traffic jams, highway repairs, and other unexpected delays, I need to plan my route in advance. The same approach applies to patient recruitment in global clinical trials.
Multiple Sclerosis is a complex disease affecting an estimated 2.5 million people globally. Thankfully, MS research is abundant, with 16 therapies approved by the FDA today and more than 30 in the pipeline.
From long-distance travel to busy schedules, participating in a clinical trial can be very difficult for patients, especially those living with a rare disease. Because of the complexity of rare diseases, patients and their caregivers must often travel long distances to see investigators who treat their unique disorder.
It’s hard to foresee the challenges that come with recruiting patients for clinical trials, unless you have extensive expertise to lean on. UBC’s Patient and Physician Services (PPS) team has supported every major MS drug in the clinical pipeline over the last 17 years. We know how to get the right patients at the right sites for your next MS study.